Minimum inhibitory concentrations (MICs) of sulfamethoxazole (SMX) and trimethoprim (TMP), alone and in three combinations, 20:1, 1:1, and 1:20, were deternined on Diagnostic Sensitivity Test (DST) and Mueller-Hinton (MH) agars containing lysed blood for various inocula of 91 strains of Bacteroides fragilis from the U.S.A. and U.K. MICs of SMX were high with large inocula and higher on MH than DST, but results for TMP were less affected by these two factors. True SMX resistance was rare: 10 U.S.A. strains previously reported as resistant appeared to be susceptible. Maximum potentiation of MICs was observed when SMX and TMP were combined in ratios close to those ofthe ratios of their MICs, that is, SMX/TMP 20:1 for large inocula and the reverse for small inocula for determinations on DST and usually 20:1 for all inoculum sizes on MH. These observations explain some of the discrepancies in reports, but defer the problem of potential usefulness of the drugs in the treatment of infection with anaerobes to future study. There is disagreement on the level of inhibitory activity of sulfamethoxazole (SMX) and trimethoprim (TMP) against Bacteroides fragilis. Rosenblatt and Stewart (4) concluded that SMX and TMP, "either individually or in combination are not active against the great majority of anaerobic bacteria." Among the resistant organisms in their study were 38 isolates ofB. fragilis. In contrast, we concluded that 49 isolates of B. fragilis from St. Thomas' Hospital, London, were susceptible to SMX and that there was evidence of potentiation when SMX and TMP were combined in suitable ratios (3). To explain the discrepancies, we have compared some of Rosenblatt and Stewart's strains isolated in the U.S.A. with some, mostly our own, isolated in the U.K.
There is disagreement on the level of inhibitory activity of sulfamethoxazole (SMX) and trimethoprim (TMP) against Bacteroides fragilis. Rosenblatt and Stewart (4) concluded that SMX and TMP, "either individually or in combination are not active against the great majority of anaerobic bacteria." Among the resistant organisms in their study were 38 isolates ofB. fragilis. In contrast, we concluded that 49 isolates of B. fragilis from St. Thomas' Hospital, London, were susceptible to SMX and that there was evidence of potentiation when SMX and TMP were combined in suitable ratios (3) . To explain the discrepancies, we have compared some of Rosenblatt and Stewart's strains isolated in the U.S.A. with some, mostly our own, isolated in the U.K.
MATERIALS AND METHODS Bacteria. The complete collection consisted of 91 isolates of B. fragilis. Ten of them that were included in Rosenblatt and Stewart's study were kindly provided by Vera Sutter and were reported to be sulfonamide resistant (U.S.A. strains). British isolates (U.K. strains) included five strains from the National Collection of Type Cultures, NCTC 8560, 9343, 9344, 10534, and 10581 (NCTC strains); two sulfonamide-resistant strains, L284 and L22711, provided by A. T. Willis of the Public Health Laboratory, Luton (L strains); five isolates from blood, BC1-5, included in our previous study; and a further 69 fresh isolates from patients in St. Thomas' Hospital (STH strains).
Antibacterial agents and susceptibility testing. Plates were examined after incubation for 24 and 48 h in GasPak jars, and MICs were read as the lowest concentration of antimicrobial agent that caused complete inhibition of growth or that permitted growth as a fine haze (5) .
These methods were used in three series ofexperiments. Results on MH blood agar (Table 3) were similar to those on DST blood agar for an inoculum of 106 CFU, with five strains in each group. However, with an inoculum of 104 CFU, in keeping with the observation that MICs of SMX were almost always higher than those of TMP on this medium, a 20:1 mixture of SMX and TMP showed maximum potentiation for all 10 strains, although one would have been predicted to have an optimum of 1:1. With 102 CFU, although 6 of the 10 strains were as susceptible to SMX as TMP (none were more susceptible to SMX in contrast with results on DST blood agar), maximum potentiation was observed with a ratio of SMX to TMP of 20:1 for all strains.
In all cases the optimal FIC index was between 0.1 and 0.4, whereas that forE. coli was 0.02 to 0.04. This indicates that although there is potentiation between SMX and TMP in appropriate ratios acting on B. fragilis, it is of a considerably lower degree than that observed with E. coli. In tests on MH blood agar, there was usually some degree of potentiation whatever the ratio ofthe two drugs, whereas in tests on DST blood agar there was often no potentiation with inappropriate ratios.
Actual concentrations of SMX and TMP in combination required for inhibition were usually of the order of 0.25 to 1 ug/ml of each, in 1:1 mixtures. The two resistant strains were inhibited by 8 to 64,ug of SMX per ml and 0.4 to 3.2 ,ug ofTMP per ml in 20:1 mixtures and 1 to 8 ,ug of each per ml in 1:1 mixtures, depending on inoculum size. DISCUSSION The reported differences in the susceptibility to sulfonamides and TMP ofB. fragilis isolated in the U.S.A. and Britain can probably be explained by differences in technique, particularly in inoculum size and medium, and in the proportions of SMX and TMP in tests on combinations. The duration of incubation may also have been of minor importance.
The main factor leading to the conclusion by Rosenblatt and Stewart (4), that B. fragilis is usually resistant to sulfonamides, appears to be the inoculum size that they used. We calculate that a Steers replicator would deliver 105 to 106 CFU from a culture of opacity equivalent to a McFarland no. 1 standard and containing therefore 3 x 106 CFU/ml. This is the inoculum recommended by Sutter and Washington (5) for susceptibility testing of anaerobes and that used by Rosenblatt and Stewart (4). Our results, in keeping with those of others for other organisms (6) , show that even sulfonamide-susceptible strains may not be inhibited by 1,000
,ug or more of SMX per ml when inocula of 106 CFU are used. This is presumably because the organisms in large inocula are able to multiply to produce visible growth during the lag period before sulfonamide begins to inhibit them. TMP MICs and sulfonamide MICs in combinations with TMP are both also affected by inoculum, but to a lesser degree. An inoculum effect was also seen with two sulfonamide-resistant strains, but for inocula of 104 CFU these SMXresistant strains were clearly more resistant than the rest on DST blood agar. It is also possible that the method ofpreparing the inoculum affects results. Rosenblatt and Stewart grew the organisms in a liquid medium, whereas we scraped organisms from the surface of solid medium and suspended them in a liquid medium. We did not test the two methods in parallel, but our results for other antibiotics are similar to those determined by the method of Sutter and Washington (2, 5) .
The second important factor influencing the results of susceptibility testing is the nature of the medium. Rosenblatt and Stewart concluded that MH blood agar and DST blood agar gave similar results for SMX, but did not quote MICs. In contrast, we found SMX MICs four-to eightfold higher on MH blood agar whereas TMP was equally active in both media. It is, however, quite possible that our MH differed from theirs.
The third and least important factor influencing MICs is duration of incubation. We found that a doubling of MIC was not uncommon after 48 h compared with 24 h with MH medium, the only one that we tested in this way.
Rosenblatt and Stewart concluded that there is little evidence of potentiation between SMX and TMP. Theoretically, maximum potentiation is to be expected when the two agents are combined in the ratio of their MICs. Using their strains and MH medium, we found evidence of potentiation for all inoculum sizes and maximal potentiation with a 20:1 mixture of SMX and TMP. This would be predicted from MICs, which were two to four times greater for SMX than TMP on MH blood agar. In disk tests the standard ratio of 20:1 SMX to TMP was used by Rosenblatt and Stewart, and we agree that no potentiation is shown by the use of such disks (3).
On DST blood agar, with SMX MICs considerably lower than on MH but TMP MICs the same, the predicted best ratio was, usually, SMX to TMP 1:2 to 1:4 or more except with very large inocula, when the reverse was found. The observed optima were in accord with predictions. For large inocula, a ratio of SMX to TMP of 20:1 was optimum, whereas for smaller inocula ratios of 1:1 or even 1:20 were better.
We conclude that in the U.K., and possibly in the U.S.A., B. fragilis is normally susceptible to sulfonamides. The exact level of activity depends on the inoculum and the medium used, and organisms may thus appear to be either more or less susceptible to sulfonamides than to TMP, whose activity is much less affected by these two factors. Sulfonamide MICs in combinations with TMP are similarly affected by inaculum, making both predictions and actual observations on optimum ratios of the two drugs difficult. In our system, with DST blood agar and an inoculum of 104 CFU, predicted and observed optimum mixtures contain more TMP than SMX. It now remains to establish the validity of our conclusions in clinical trials, perhaps with mixtures of SMX and TMP in ratios other than those at present commercially available.
